Inventor

CHANG CHIEN-HSING

US152 patents

⚠️ This page may combine multiple inventors who share the name “CHANG CHIEN-HSING”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

CHANG CHIEN-HSING

IBC PHARMACEUTICALS INC

Methods and compositions for generating bioactive assemblies of increased complexity and uses

PEGylation by the dock and lock (DNL) technique

Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses

Methods and compositions for generating bioactive assemblies of increased complexity and uses

Multivalent immunoglobulin-based bioactive assemblies

Stably tethered structures of defined compositions with multiple functions or binding specificities

T-cell redirecting bispecific antibodies for treatment of disease

Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases

Tetrameric cytokines with improved biological activity

Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo

PEGylation by the dock and lock (DNL) technique

Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology

Dock-and-lock (DNL) vaccines for cancer therapy

Stably tethered structures of defined compositions with multiple functions or binding specificities

Multivalent immunoglobulin-based bioactive assemblies

Combination therapy for inducing immune response to disease

Disease therapy by inducing immune response to Trop-2 expressing cells

Disease therapy by inducing immune response to Trop-2 expressing cells

Combination therapy for inducing immune response to disease

CHANG CHIEN-HSING

Tetrameric cytokines with improved biological activity

Dock-and-lock (DNL) complexes for delivery of interference RNA

Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy

Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases

Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in VIVO

Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology

PEGylation by the dock and lock (DNL) technique

Methods and compositions for generating bioactive assemblies of increased complexity and uses

Multivalent immunoglobulin-based bioactive assemblies

Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses

Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo

Strategies for improved cancer vaccines

Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity

IMMUNOMEDICS INC

Humanized anti-HLA-DR antibodies

Humanized L243 antibodies

Mammalian cell lines for increasing longevity and protein yield from a cell culture

Anti-mucin antibodies for early detection and treatment of pancreatic cancer

Humanized anti-CD22 antibody

Class I anti-CEA antibodies and uses thereof

Structural variants of antibodies for improved therapeutic characteristics

Mammalian cell lines for increasing longevity and protein yield from cell culture

Methods and compositions for increasing longevity and protein yield from a cell culture

Method for radiolabeling monovalent antibody fragments

Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1

GOLDENBERG DAVID M

Humanized anti-HLA-DR antibodies

Humanized L243 antibodies

Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments

Structural variants of antibodies for improved therapeutic characteristics

HANSEN HANS J

Class I anti-CEA antibodies and uses thereof

MCBRIDE WILLIAM J

Delivery system for cytotoxic drugs by bispecific antibody pretargeting

CT MOLECULAR MED & IMMUNOLOGY

Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis